Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Sun Pharmaceutical Industries Limited (Scrip Code: 524715, NSE: SUNPHARMA) submitted an intimation to the National Stock Exchange of India Limited and BSE Limited on July 24, 2026, under Regulation 30 of SEBI LODR Regulations.
Key Development: Shareholder Approval
Sun Pharma announced that the stockholders of Organon & Co. have approved the proposals related to the previously announced merger transaction. Under this transaction, Organon is expected to become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA, Inc., which is itself an indirect wholly owned subsidiary of Sun Pharmaceutical Industries Limited.
Transaction Status and Conditions
The shareholder approval is described as an important milestone toward completing the proposed transaction. The acquisition remains subject to the satisfaction of remaining customary closing conditions, including applicable regulatory approvals. The transaction was originally announced on April 27, 2026.
Company Background
Sun Pharmaceutical Industries Limited (CIN: L24230GJ1993PLC019050) is identified as a leading global pharmaceutical company with operations in Innovative Medicines, Generics, and Consumer Healthcare products. It is the largest pharmaceutical company in India and a leading generic company in the US and Global Emerging Markets. The company's Innovative Medicines portfolio accounts for about 22% of company sales and spans dermatology, ophthalmology, and onco-dermatology. Sun Pharma has vertically integrated operations delivering medicines to over 100 countries with manufacturing facilities across five continents.
Contacts
Investor Contact: Dr. Abhishek Sharma | Tel: +91 22 4324 4324, Xtn 2929 | Direct Tel: +91 22 4324 2929 | Mobile: +91 98196 86016 | Email: abhi.sharma@sunpharma.com
Media Contact: Gaurav Chugh | Tel: +91 22 4324 4324, Xtn 5373 | Direct Tel: +91 22 4324 5373 | Mobile: +91 98104 71414 | Email: gaurav.chugh@sunpharma.com